Skip to main content
. Author manuscript; available in PMC: 2024 Aug 5.
Published in final edited form as: Eur J Med Chem. 2023 May 13;256:115476. doi: 10.1016/j.ejmech.2023.115476

Table 4.

U.S. FDA-Approved Fluorinated Drugs for Other Diseases (2018–2022).

Drug Approval Date Composition Company Indication Drug Mechanism
Symdeko 2/13/2018 Tezacaftor and Ivacaftor Vertex Pharmaceuticals Cystic Fibrosis CFTR corrector and CFTR potentiator
Tavalisse 4/17/2018 Fostamatinib Rigel Pharmaceuticals Chronic immune thrombocytopenia SYK inhibitor
Orilissa 7/23/2018 Elagolix sodium AbbVie Endometriosis GnRH receptor antagonist
Rinvoq 8/16/2019 Upadacitinib AbbVie Rheumatoid arthritis JAK inhibitor
Trikafta 10/21/2019 Tezacaftor, Ivacaftor and Elexacaftor Vertex Pharmaceuticals Cystic Fibrosis CCFTR corrector, CFTR potentiator and CFTR corrector
Tavneos 10/7/2021 Avacopan ChemoCentryx Severe active antineutrophil cytoplasmic autoantibody- associated vasculitis C5a receptor antagonist

The source of the data is the U.S. FDA Web site [51].